Bloomios Inc - BLMS STOCK NEWS

Bloomios, Inc. (OTCQB: BLMS) announced the appointment of Joe Reid as Chief Manufacturing Officer for its subsidiary, Bloomios Private Label. Reid, a former head of production at Upexi, brings over a decade of manufacturing experience, particularly in cannabinoid supplements. His leadership aims to enhance operational efficiency following Bloomios' acquisition of Upexi’s subsidiary. This transition is expected to double production capacity and reduce costs, addressing previous limitations in meeting demand. Reid led significant production growth at Upexi, increasing output by 300% at a 30,000-square-foot facility.

Upexi Inc. (NASDAQ: UPXI) announced a strategic sale of select CBD assets to Bloomios, Inc. (OTC: BLMS) for approximately $23.5 million. This transaction enhances Upexi's focus on its Amazon and DTC eCommerce strategy while strengthening its balance sheet. The sale yields $5.5 million in cash, $9.5 million in loan receivables, and $8.5 million in preferred equity in Bloomios. Upexi reiterates its fiscal 2023 revenue guidance between $72 million to $82 million.

Bloomios, Inc. (OTCQB: BLMS), based in Santa Barbara, is expanding its portfolio by developing a new range of private-label health and wellness products featuring natural ingredients like ashwagandha, melatonin, kratom, lion's mane, valerian root, and reishi mushroom. The company is collaborating with several brands, addressing the growing consumer demand for potent natural supplements aimed at focus, relaxation, and pain relief. Many products are nearing completion in development. Bloomios leverages in-house R&D to create customized solutions for its clients.

Bloomios, Inc. (OTCQB: BLMS) has been invited to present at the 2022 LD Micro Invitational on June 7-9, 2022, in Westlake Village, California. Chief Business Officer Doug Rohrer will present on June 7 at 10:30 a.m. ET and conduct one-on-one investor meetings. The discussion will highlight Bloomios' recent manufacturing expansion in Daytona Beach, Florida, which has increased production capacity by 300% and lowered operating expenses, supporting over 80 products across seven categories.

Bloomios, Inc. (OTCQB: BLMS) has significantly expanded its manufacturing capabilities with a new 50,000 sq. ft. facility in Daytona Beach, Florida. This expansion boosts capacity by approximately 300%, allowing production of over 1 million infused gummies daily by Q3 2022. Despite recent revenue declines due to transitional downtimes, the company anticipates strong growth and market share expansion in 2022, particularly in the fast-growing sports nutrition sector. Bloomios is positioned to tap into a projected $61.3 billion CBD market by 2027.

Bloomios, Inc. (OTCQB: BLMS) reported substantial growth for Q4 and full year 2021. Q4 revenue surged 37% to $1.7 million, while full-year revenue soared 545% to a record $8.5 million. Gross profit for Q4 rose 82% to $698,000, with margins improving from 32% to 42%. The company expanded its product line to over 80 options and increased manufacturing capacity by 300%. Additionally, Bloomios has entered a partnership with DRYWORLD in the sports nutrition sector. Despite a net loss of $2.0 million for 2021, the outlook remains optimistic with new product launches planned for 2022.

Bloomios, Inc. (OTCQB: BLMS), a company specializing in hemp-derived cannabinoid products, has partnered with CMA, a capital markets advisory firm, to enhance its investor outreach and public relations. Since its launch in Q4 2020, Bloomios has reported over $8 million in gross revenue as of September 30, 2021, with demand surpassing supply. The company recently expanded its production capacity by over 300% and aims to capitalize on the growing CBD market, projected to reach $61.3 billion by 2027. This strategic campaign aims to raise public awareness and shareholder value.